已收盘 02-06 16:00:00 美东时间
+0.030
+2.83%
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapiesLed by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop, trial will focus on early-stage,
01-12 20:10
AN2 Therapeutics press release (ANTX): Q3 net loss was $9.4 million. The Company had cash, cash equivalents and investments of $65.1 million at September 30, 2025. More on AN2 Therapeutics Seeking Alp...
2025-11-13 23:20
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 4.73 percent. This is a 27.91 percent increase over losses of $(0.43) per share from
2025-11-13 05:30
AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a
2025-11-10 20:11
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30.69 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
2025-08-13 04:20
AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2...
2025-06-11 19:59
AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On May 22, 2025,...
2025-05-28 05:09
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
2025-05-14 06:01
AN2 Therapeutics Inc: Cash Runway Anticipated to Fund Operations Into 2028
2025-05-14 04:02
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Busine...
2025-05-14 04:01